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Modelling of Glucose-Insulin-Glucagon Pharmacodynamics in Man
S. L. Wendt1,2, J. K. Møller2, A. Haidar3, C. B. Knudsen1, H. Madsen2, J. B. Jørgensen2
Abstract—The purpose is to build a simulation model of the
glucoregulatory system in man. We estimate individual human
parameters of a physiological glucose-insulin-glucagon model.
We report posterior probability distributions and correlations
of model parameters.
I. INTRODUCTION
In healthy individuals, insulin and glucagon work in a
complex fashion to maintain blood glucose levels within a
narrow range. Recent studies suggest a multiplicative effect
of insulin and of glucagon on endogenous glucose production
(EGP) [1].
II. MATERIALS AND METHODS
A. PD Model
The pharmacodynamics (PD) model is mainly inspired by
Hovorka et al. [2].
Q˙1(t) = −F01 − STx1(t)Q1(t) + k12Q2(t) + FIC(t) (1a)
Q˙2(t) = STx1(t)Q1(t)− (k12 + SDx2(t))Q2(t) (1b)
x˙i(t) = ki (I(t)− xi(t)) i = 1, 2, 3 (1c)
Q1(t) and Q2(t) are the masses of glucose per bodyweight
(µmol/kg) in the accessible and non-accessible compart-
ments. Glucose concentration (mmol/L) in the accessible
compartment is Q1(t)/V with V fixed at 160 mL/kg. I(t) is
the insulin concentration (mIU/L) in the accessible compart-
ment. xi(t) are the remote effects of insulin (mIU/L).
F01 is the non-insulin-dependent glucose flux. k12 and ki
are transfer rate constants. SD, SE , and ST are insulin
sensitivities.
The model in (1) is modified so FIC(t) is the insulin and
glucagon dependent EGP [3].
FIC(t) =
(1− SEx3(t))
(1− SEIb,y) ·
(
(Emax − E0) C(t)
CE50 + C(t)
)
(2)
C(t) is the glucagon concentration (pg/mL) in the accessible
compartment. Ib,y is the fixed basal insulin concentration
(mIU/L) for subject y, and E0 is the minimum EGP fixed at
8 µmol/(kg·min). Emax is the maximum EGP at Ib,y . CE50
is the glucagon concentration at half maximum EGP.
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B. Parameter Estimation
We used maximum a posteriori to estimate PD model
parameters and profile likelihood analysis to reduce uniden-
tifiable parameters in data with measurements of glucose,
insulin and glucagon from ten healthy male subjects who
received a 1 mg subcutaneous bolus of marketed glucagon.
III. RESULTS
TABLE I
POSTERIOR DISTRIBUTIONS OF PARAMETERS ACROSS POPULATION.
Parameter Unit Mean SD
CE50 pg/mL 407 39
Emax µmol/(kg·min) 38.8 5.0
F01 µmol/(kg·min) 10.5 0.95
ln(k12) min−1 -3.48 0.26
ln(k2) min−1 -2.11 0.03
ln(k3) min−1 -4.20 0.74
ln(SE) per mIU/L -3.19 0.67
ln(ST ) min−1 per mIU/L -5.73 0.54
ln(k1) min−1 -5.69 *
ln(SD) min−1 per mIU/L -7.58 *
* Fixed unidentifiable parameter.
TABLE II
POSTERIOR CORRELATION MATRIX OF IDENTIFIABLE PARAMETERS.
CE50 Emax F01 k12∗ k2∗ k3∗ SE∗ ST ∗ BW
CE50 1
Emax 0.31 1
F01 0.32 -0.30 1
k12∗ 0.45 0.23 0.22 1
k2∗ -0.63 0.06 -0.13 -0.30 1
k3∗ 0.13 -0.34 0.82 -0.02 -0.33 1
SE∗ -0.82 -0.26 -0.40 -0.22 0.43 -0.35 1
ST ∗ -0.20 -0.22 -0.13 0.45 -0.28 -0.14 0.57 1
BW 0.61 -0.43 0.39 0.24 -0.70 0.42 -0.60 0.00 1
* Correlation of ln-transformed parameter.
IV. CONCLUSIONS
The model enables simulations of the glucose-insulin-
glucagon dynamics in man at the following concentrations:
glucagon (180-8000 pg/mL), insulin (1.2-81.9 mIU/L) and
glucose (3.3-11.5 mmol/L).
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